IL310306A - Protein inhibitors for fibroblast activation and their use - Google Patents
Protein inhibitors for fibroblast activation and their useInfo
- Publication number
- IL310306A IL310306A IL310306A IL31030624A IL310306A IL 310306 A IL310306 A IL 310306A IL 310306 A IL310306 A IL 310306A IL 31030624 A IL31030624 A IL 31030624A IL 310306 A IL310306 A IL 310306A
- Authority
- IL
- Israel
- Prior art keywords
- protein inhibitors
- activation protein
- fibroblast activation
- fibroblast
- inhibitors
- Prior art date
Links
- 230000004913 activation Effects 0.000 title 1
- 210000002950 fibroblast Anatomy 0.000 title 1
- 229940121649 protein inhibitor Drugs 0.000 title 1
- 239000012268 protein inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21187424.3A EP4122499A1 (en) | 2021-07-23 | 2021-07-23 | Fibroblast activation protein inhibitors and use thereof |
| PCT/EP2022/070693 WO2023002045A1 (en) | 2021-07-23 | 2022-07-22 | Fibroblast activation protein inhibitors and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310306A true IL310306A (en) | 2024-03-01 |
Family
ID=77042830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310306A IL310306A (en) | 2021-07-23 | 2022-07-22 | Protein inhibitors for fibroblast activation and their use |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240335569A1 (https=) |
| EP (2) | EP4122499A1 (https=) |
| JP (1) | JP2024527627A (https=) |
| KR (1) | KR20240040092A (https=) |
| CN (1) | CN117769443A (https=) |
| AU (1) | AU2022313521A1 (https=) |
| CA (1) | CA3224514A1 (https=) |
| CL (1) | CL2024000200A1 (https=) |
| IL (1) | IL310306A (https=) |
| MX (1) | MX2024000866A (https=) |
| WO (1) | WO2023002045A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4475900A1 (en) | 2022-02-09 | 2024-12-18 | Novartis AG | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
| EP4342890A1 (en) * | 2022-09-21 | 2024-03-27 | Erasmus University Rotterdam Medical Center | Platform and scaffold for fap targeting agents |
| WO2025106939A1 (en) * | 2023-11-16 | 2025-05-22 | Praxis Biotech LLC | Conjugates targeting fibroblast activation protein and uses thereof |
| CN119604492A (zh) * | 2023-12-08 | 2025-03-11 | 北京师范大学 | 一种放射性标记fapi配合物及其制备方法和应用 |
| WO2025167951A1 (zh) * | 2024-02-07 | 2025-08-14 | 苏州博锐创合医药有限公司 | 一种成纤维细胞活化蛋白抑制剂 |
| WO2025240871A1 (en) * | 2024-05-16 | 2025-11-20 | Purdue Research Foundation | Chemically stable keto-amide-based fibroblast activation protein-targeted nanoparticle-based magnetic resonance imaging agent, compositions, and methods of use |
| CN118978511A (zh) * | 2024-08-02 | 2024-11-19 | 江苏华益科技有限公司 | 一种靶向fap化合物及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| CN103370063A (zh) | 2010-12-13 | 2013-10-23 | 免疫医疗公司 | 用于改善蛋白质、肽和其他分子的f-18标记的方法和组合物 |
| DE102014115088A1 (de) | 2014-10-16 | 2016-04-21 | Sovicell Gmbh | Bestimmung von Bindungskonstanten mittels Gleichgewichtsverlagerung |
| EA202090776A1 (ru) * | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
| SG11202007180QA (en) * | 2018-02-06 | 2020-08-28 | Univ Heidelberg | Fap inhibitor |
| DE102018126558A1 (de) * | 2018-10-24 | 2020-04-30 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Markierungsvorläufer mit Quadratsäure-Kopplung |
| CN113811529A (zh) * | 2018-12-21 | 2021-12-17 | 普拉西斯生物技术有限责任公司 | 成纤维细胞激活蛋白抑制剂 |
-
2021
- 2021-07-23 EP EP21187424.3A patent/EP4122499A1/en not_active Ceased
-
2022
- 2022-07-22 WO PCT/EP2022/070693 patent/WO2023002045A1/en not_active Ceased
- 2022-07-22 AU AU2022313521A patent/AU2022313521A1/en active Pending
- 2022-07-22 MX MX2024000866A patent/MX2024000866A/es unknown
- 2022-07-22 CN CN202280050775.2A patent/CN117769443A/zh active Pending
- 2022-07-22 IL IL310306A patent/IL310306A/en unknown
- 2022-07-22 JP JP2024503606A patent/JP2024527627A/ja active Pending
- 2022-07-22 CA CA3224514A patent/CA3224514A1/en active Pending
- 2022-07-22 EP EP22757517.2A patent/EP4373529A1/en active Pending
- 2022-07-22 KR KR1020247005694A patent/KR20240040092A/ko active Pending
- 2022-07-22 US US18/291,078 patent/US20240335569A1/en active Pending
-
2024
- 2024-01-23 CL CL2024000200A patent/CL2024000200A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240040092A (ko) | 2024-03-27 |
| AU2022313521A1 (en) | 2023-12-14 |
| CA3224514A1 (en) | 2023-01-26 |
| EP4122499A1 (en) | 2023-01-25 |
| MX2024000866A (es) | 2024-02-09 |
| WO2023002045A1 (en) | 2023-01-26 |
| EP4373529A1 (en) | 2024-05-29 |
| CN117769443A (zh) | 2024-03-26 |
| AU2022313521A9 (en) | 2024-01-04 |
| CL2024000200A1 (es) | 2024-06-14 |
| US20240335569A1 (en) | 2024-10-10 |
| JP2024527627A (ja) | 2024-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL310306A (en) | Protein inhibitors for fibroblast activation and their use | |
| IL320762A (en) | Fibrous binders and their use | |
| EP3946451A4 (en) | FIBROBLAST ACTIVATING PROTEIN BINDING AGENTS AND USE THEREOF | |
| IL284434A (en) | Fibroblast activation protein inhibitors | |
| EP3898654A4 (en) | FIBROBLAST ACTIVATION PROTEIN INHIBITORS | |
| IL300107A (en) | HSD17B13 quinazolinone inhibitors and uses thereof | |
| IL307187A (en) | MK2 inhibitors and their uses | |
| EP4469449A4 (en) | PARP1 INHIBITORS AND THEIR USES | |
| IL320829A (en) | PARP1 inhibitors and their uses | |
| IL285595A (en) | Spt5 inhibitors and uses thereof | |
| IL296586B1 (en) | Cyclophilin inhibitors and their uses | |
| EP3712179A4 (en) | BINDING UNIT DIRECTED AGAINST FIBROBLAST ACTIVATION PROTEIN ALPHA AND APPLICATION OF IT | |
| EP4028385A4 (en) | USP30 INHIBITORS AND USES THEREOF | |
| SG11202111462VA (en) | Asx-specific protein ligases and uses thereof | |
| EP4279507A4 (en) | CD73-BINDING PROTEIN AND USE THEREOF | |
| PL4337673T3 (pl) | Inhibitory psd-95 i ich zastosowania | |
| IL310209A (en) | ROCK2 inhibitors and their uses | |
| IL305789A (en) | USP30 inhibitors and uses thereof | |
| IL309885A (en) | Alpha-surface polypeptides and their use | |
| EP4269428A4 (en) | NEW PEPTIDE AND ITS USE | |
| EP4163288A4 (en) | NEW NUCLEOLIN-BINDING PEPTIDE AND USE THEREOF | |
| HK40104900A (en) | Fibroblast activation protein inhibitors and use thereof | |
| EP4446335A4 (en) | NEW PEPTIDE AND ITS USE | |
| IL311185A (en) | MOG-binding proteins and uses thereof | |
| IL315110A (en) | Emopamil-binding protein inhibitors and uses thereof |